In children with CM who were younger than 5 years at both CM episode and follow-up neurocognitive testing, plasma tau levels (log10 transformed) were associated with worse overall cognition scores over 24-month follow-up (β = −0.80; 95% CI, −1.32 to −0.27; P = .003). This evidence concerns the gene MAPT and cutaneous mastocytosis.